Myriad Genetics (NASDAQ: MYGN) has lowered its full-year sales guidance for FY2026, signaling a material shift in revenue expectations for the genetic testing company. The firm revised its outlook downward from a previous range of $860.000 million to $880.000 million to a new band of $770.000 million to $790.000 million. This updated projection now falls below the consensus analyst estimate of $863.568 million, indicating potential headwinds in the company’s near-term commercial performance.

The revision reflects a substantial gap between market expectations and management’s revised internal forecasts. By lowering the midpoint of its guidance by approximately $90 million from the prior estimate, Myriad Genetics highlights challenges in meeting earlier growth targets. The new upper bound of $790.000 million is nearly $74 million lower than the initial high-end projection of $860.000 million.

Guidance Revision Details

The following table outlines the changes in Myriad Genetics’ FY2026 sales outlook:

The company’s decision to issue this downward revision underscores the importance of accurate forecasting in the healthcare diagnostics sector. Investors will likely scrutinize subsequent quarterly reports to understand the specific operational or market factors driving this change in trajectory.

What the Numbers Show

The divergence between the new guidance and the analyst estimate suggests that external market conditions or internal operational metrics have deteriorated since the last forecast was issued. With the new high-end guidance of $790.000 million falling well below the $863.568 million estimate, the company faces pressure to demonstrate clear pathways for revenue recovery in future quarters.

Myriad Genetics, Inc. has announced results from the largest individual-patient-data meta-analysis of its Prolaris Biopsy Test to date, demonstrating significant prognostic value for patients with localized prostate cancer. The study, published in Clinical Genitourinary Cancer, pooled data across 14 studies involving 8,478 patients, with individual participant data available for 7,924 patients. The findings indicate that the Prolaris combined clinical risk score (CCR) provides independent, additive prognostic information beyond established clinical tools such as Gleason score, CAPRA score, and NCCN risk group.

The analysis evaluated Prolaris performance across all National Comprehensive Cancer Network (NCCN) risk groups and initial disease management strategies. Results showed the CCR score was significantly prognostic for distant metastasis and prostate cancer-specific mortality. This evidence supports the role of the Prolaris Biopsy Test in risk stratification to inform initial prostate cancer management discussions and shared decision-making.

Steven Monda, MD, study author and Clinical Instructor at the University of Michigan Health, emphasized the clinical utility of the test. "Our study shows that this tissue-based RNA test built on an array of cell cycle genes can provide prognostic information beyond clinical features alone, like CAPRA or NCCN, in localized prostate cancer," Monda said. He noted that CCR is prognostic for prostate cancer-specific mortality even in low-risk patients, which is useful for active surveillance conversations.

The Prolaris Biopsy Test analyzes gene expression from a prostate biopsy sample and incorporates clinical information to generate a CCR score. The score is intended to support decisions related to initial prostate cancer management options, including active surveillance, definitive therapy, and multi-modal escalation. By providing additional insight into a patient’s risk of disease progression, the test aims to help clinicians identify patients appropriate for active surveillance versus those who may require treatment or treatment escalation.

Study Details

The meta-analysis utilized individual participant data where available, evaluating Prolaris performance with clinically meaningful endpoints and a consistent statistical approach. The study confirmed that Prolaris is a robust prognostic tool with broad applicability for patients with localized prostate cancer.